TargetBeta
CD19
CD19 molecule · CD molecules
44 programs in company-led studies act on CD19, from 34 companies: 10 in phase 3, 2 approved with new studies. Each with where its target was read from.
Programs
Furthest phase first. A target read by rule is marked rule (33 of them); the others are the company’s own words or a reading by Claude, each quoted on the program’s page.
| Program | Company | Furthest phase | Studies | Also acts on | Read from |
|---|---|---|---|---|---|
| inebilizumabrule | Amgen | phase 4 | 1911 running | – | NCIt |
| blinatumomabrule | Amgen | phase 4 | 297 running | CD3E | ChEMBL |
| Autologous Bispecific BCMA/CD19-targeted CAR-T Cells GC012F | AstraZeneca | phase 3 | 1212 running | TNFRSF17 | a judged reading |
| surovatamig | AstraZeneca | phase 3 | 1010 running | CD3E | a judged reading |
| Anti-CD19/CD3 Bispecific Antibody MK-1045 | Merck | phase 3 | 88 running | CD3E | a judged reading |
| Autologous Anti-CD19 CAR-T Cells CABA-201rule | Cabaletta Bio | phase 3 | 65 running | – | NCIt |
| zolacabtagene autoleucel | Bristol-Myers Squibb | phase 3 | 65 running | – | a judged reading |
| obexelimab | Zenas BioPharma (USA) | phase 3 | 74 running | FCGR2B | a judged reading |
| axicabtagene ciloleucelrule | Gilead Sciences | phase 3 | 103 running | – | ChEMBL |
| lisocabtagene maraleucelrule | Bristol-Myers Squibb | phase 3 | 103 running | – | ChEMBL |
| Autologous Anti-CD19/Anti-CD20 CAR-T Cells KITE-753rule | Gilead Sciences | phase 3 | 22 running | – | NCIt |
| rondecabtagene autoleucelrule | Lyell Immunopharma | phase 3 | 22 running | MS4A1 | NCIt |
| rapcabtagene autoleucel | Novartis | phase 2 | 87 running | – | the company's pipeline |
| zamtocabtagene autoleucelrule | Miltenyi Biomedicine | phase 2 | 87 running | CD4, CD8A, MS4A1 | NCIt |
| obecabtagene autoleucelrule | Autolus | phase 2 | 55 running | – | NCIt |
| YK012rule | Excyte Biopharma | phase 2 | 55 running | CD3E | the studies' text |
| budoprutugrule | Climb Bio | phase 2 | 84 running | – | the studies' text |
| Allogeneic CRISPR-Cas9 Engineered Anti-CD19 CAR T-cells CTX112rule | CRISPR Therapeutics | phase 2 | 44 running | – | NCIt |
| Autologous Anti-CD19/CD20 CAR-T Cells KITE-363rule | Gilead Sciences | phase 2 | 33 running | MS4A1 | NCIt |
| belacabnagene franleucelrule | Nkarta | phase 2 | 33 running | IL15 | NCIt |
| iPSC-derived Allogeneic Anti-CD19 1XX-CAR T-cells FT819rule | Fate Therapeutics | phase 2 | 33 running | – | NCIt |
| anbalcabtagene autoleucelrule | Curocell | phase 2 | 22 running | – | NCIt |
| GSK5926371 | GlaxoSmithKline | phase 2 | 22 running | CD3E, MS4A1 | the company's pipeline |
| prizloncabtagene autoleucelrule | AbelZeta | phase 2 | 22 running | MS4A1 | NCIt |
| Allogeneic Anti-CD19/CD20 CAR T-cells AVC-203rule | AvenCell Therapeutics | phase 2 | 11 running | MS4A1 | NCIt |
| Autologous Anti-CD19 CAR-expressing T Lymphocytesrule | Beijing Biotech | phase 2 | 11 running | – | NCIt |
| CRT-402rule | Myeloid Therapeutics | phase 2 | 11 running | – | the studies' text |
| CT204V-CD19 × CD20rule | AstraZeneca | phase 2 | 11 running | MS4A1 | the studies' text |
| QEL-005rule | Quell Therapeutics | phase 2 | 11 running | – | the studies' text |
| YTS109rule | China Immunotech (Beijing) Biotechnology | phase 1 | 86 running | – | the studies' text |
| Anti-CD19/Anti-CD3/Anti-CD28 Trispecific Antibody CC312rule | CytoCares | phase 1 | 44 running | CD28, CD3E | NCIt |
| Anti-CD19/CD3 T-cell Engaging Bispecific Antibody CLN-978rule | Cullinan Therapeutics | phase 1 | 43 running | CD3E | NCIt |
| Anti-CD19/Anti-CD3/Anti-CD2 Trispecific Antibody PIT565 | Novartis | phase 1 | 33 running | CD2, CD3E | the company's pipeline |
| BCMA-CD19 Compound CAR T Cellsrule | iCell Gene Therapeutics | phase 1 | 33 running | TNFRSF17 | NCIt |
| Anti-CD19-Glucosteroid Receptor Modulator ADC ABBV-31 | AbbVie | phase 1 | 22 running | – | the company's pipeline |
| ABBV-519 | AbbVie | phase 1 | 11 running | – | the company's pipeline |
| ARM011rule | TriArm Therapeutics (Taiwan) | phase 1 | 11 running | – | the studies' text |
| ATG-201rule | Antengene Biologics | phase 1 | 11 running | CD3E | the studies' text |
| CPTX2309 | AbbVie | phase 1 | 11 running | – | the company's pipeline |
| HB2198rule | Hinge Bio | phase 1 | 11 running | MS4A1 | the studies' text |
| KT501rule | Kali Therapeutics | phase 1 | 11 running | CD3E | the studies' text |
| KT502rule | Kali Therapeutics | phase 1 | 11 running | CD3E | the studies' text |
| ORN252rule | Eli Lilly | phase 1 | 11 running | – | the studies' text |
| vispacabtagene regedleucelrule | Caribou Biosciences | phase 1 | 10 running | – | NCIt |
Conditions their studies are in
- Lupus Erythematosus, Systemic, 16 programs
- Lupus Nephritis, 14 programs
- Lymphoma, B-Cell, 10 programs
- Lymphoma, Large B-Cell, Diffuse, 10 programs
- Arthritis, Rheumatoid, 7 programs
- Lymphoma, Non-Hodgkin, 6 programs
- Lymphoma, Follicular, 4 programs
- Multiple Sclerosis, 4 programs
- Scleroderma, Systemic, 4 programs
- Anemia, Hemolytic, Autoimmune, 3 programs
Primary completions ahead
Each program’s next study to reach its primary completion, by the sponsor’s estimate.
- Nov 24, 2026YTS109 · China Immunotech (Beijing) Biotechnology · phase 1 · NCT07236762
- Dec 2026YK012 · Excyte Biopharma · phase 2 · NCT06982729
- Dec 2026Anti-CD19/CD3 T-cell Engaging Bispecific Antibody CLN-978 · Cullinan Therapeutics · phase 1 · NCT06613360
- Dec 2026ORN252 · Eli Lilly · phase 1 · NCT07439796
- Dec 31, 2026zamtocabtagene autoleucel · Miltenyi Biomedicine · phase 2 · NCT04792489
- Jan 4, 2027Anti-CD19/Anti-CD3/Anti-CD2 Trispecific Antibody PIT565 · Novartis · phase 1 · NCT05397496
- Feb 2027Anti-CD19-Glucosteroid Receptor Modulator ADC ABBV-31 · AbbVie · phase 1 · NCT05512390
- Feb 2027KT501 · Kali Therapeutics · phase 1 · NCT07234773
What this can’t show
- Only programs whose target has been read: most early programs are named only by a code and their companies do not say what they act on.
- A target read by rule can be wrong; each program’s page quotes the words it was read from.
- “Acts on” does not say how: an agonist and an antagonist of the same receptor are listed together (avexitide blocks the GLP-1 receptor that semaglutide activates).
- Programs in company-led studies on ClinicalTrials.gov with a study in the last two years; academic studies and other registries are not counted here.